Identification of a Single Exon Deletion Using NGS in a Patient with Perlman Syndrome

Total Page:16

File Type:pdf, Size:1020Kb

Identification of a Single Exon Deletion Using NGS in a Patient with Perlman Syndrome REPRINTED FROM DECEMBER 2019 PATHOLOGY ◆ LABORATORY MEDICINE ◆ LABORATORY MANAGEMENT Identification of a single exon deletion using NGS in a patient with Perlman syndrome CAP TODAY and the Association for nephromegaly, hydronephrosis with by PCR specifically targeting DIS3L2 Molecular Pathology have teamed up megaureters, bilateral diffuse nephro- exon 9 using exon 6 as a positive PCR to bring molecular case reports to CAP blastomatosis, and renal dysplastic control (Fig. 2B, next page). Precise TODAY readers. AMP members write changes (Fig. 1). Also noted was or- breakpoints could not be determined the reports using clinical cases from their ganomegaly of the liver, spleen, and due to the nature of the targeted assay own practices that show molecular test- thymus. The lungs showed mild pul- used. Homozygous deletions of exon ing’s important role monary hypoplasia 9 in DIS3L2 have been reported in in diagnosis, prog- nosis, and treat- with diffuse hyaline multiple individuals from at least four 2-4 ment. The following membrane disease. families with Perlman syndrome report comes from A skin biopsy was and are listed in DECIPHER (#318416, Children’s Hospital case report sent to our labora- https://decipher.sanger.ac.uk/). The deletion of Philadelphia and tory for genetic test- of exon 9 is predicted to result in an Driscoll Children’s Hospital, Corpus ing with suspicion of Perlman syn- in-frame mRNA product, and it may Christi, Tex. If you would like to submit drome (mutation in DIS3L2 gene) or be mediated by nonallelic homolo- a case report, please send an email to the other potential causes for diseases gous recombination between LINE-1 AMP at [email protected]. For more informa- with elevated cancer risk in an over- repeats located in the introns.3 The tion about the AMP and all previously grown fetus, such as Simpson-Golabi- identification of the DIS3L2 exon 9 published case reports, visit www.amp.org. Behmel syndrome (GPC3). For these Jinhua Wu, PhD; Jeffrey Schubert, PhD reasons, a comprehensive hereditary A Xiaonan Zhao, PhD; Elizabeth Fanning, MS cancer panel of 130 genes (including Zhiqian Fan, MS; Lisa Sutton, MD DIS3L2) was performed. Marilyn M. Li, MD The comprehensive hereditary We report a case of a 34-week-gesta- cancer panel did not identify a patho- tion male infant with prenatal over- genic or likely pathogenic variant growth born to a 19-year-old G1P0 according to the American College mother. No significant family history of Medical Genetics and Genomics/ or consanguinity were reported. The Association for Molecular Pathology infant was delivered emergently by germline variant classification guide- B cesarean section due to pregnancy- lines,1 and no variants were observed induced hypertension and polyhy- in the DIS3L2 gene. However, ana- dramnios. At birth, the infant was lysis of regions with low sequence noted to have anasarca and ascites coverage on the panel discovered no with a massively distended abdomen sequence reads aligned to the genomic and enlarged kidneys. Despite resus- region of chr2:233028163-233028348, citative efforts, the infant expired at corresponding to exon 9 of DIS3L2 one day of life. A complete autopsy (NM_152383.4), indicating a homo- demonstrated clinical and histologic zygous deletion of DIS3L2 exon 9 Fig. 1. Renal histology from patient’s autopsy. features suggestive of Perlman syn- as visualized using Integrative Ge- A. Disorganized renal parenchyma and diffuse drome. There were significant urinary nomics Viewer (IGV) (Fig. 2A, next nephroblastomatosis (20 ×). B. Higher power view tract abnormalities, including massive page). The deletion was confirmed of a small foci of blastema (40 ×). 2 | CAP TODAY homozygous deletion is diagnostic genes as can NGS-based tests. Astuti, et al., established a molecu- of Perlman syndrome for the patient. Perlman syndrome, first described lar basis for Perlman syndrome in Next-generation sequencing tech- in the 1970s,5-7 is a rare, autosomal re- 20122 by identifying regions of homo- nology allows interrogation of mul- cessive overgrowth syndrome that can zygosity in consanguineous Perlman tiple genes in parallel to evaluate present prenatally with fetal macroso- syndrome families. With further ge- multiple variant types, including mia and polyhydramnios. Patients netic mapping, germline homozygous SNVs, small indels, exonic dele- also show characteristic dysmorphic deletions of DIS3L2 exons were found tions/duplications, and gross copy facial features, including deep-set in multiple consanguineous families, number changes, as well as fusions eyes, low-set ears, inverted V-shaped and additional biallelic DIS3L2 single and alternative splicing, through a upper lip, prominent forehead, and a nucleotide variants, including splice- single test, using DNA and RNA. broad, flat nasal bridge. There is a high site and missense mutations, were PCR was used to confirm the exon 9 rate of neonatal mortality in patients found to segregate with disease in homozygous deletion in this case with Perlman syndrome. Those who non-consanguineous patients. The since we knew what we were look- do survive commonly exhibit devel- authors further demonstrated through ing for; however, this method would opmental delay and renal abnormali- functional in vitro studies that recom- have had limited utility as a first-line ties and are at a high risk for develop- binant DIS3L2 protein with exon 9 test because it cannot detect the same ing nephroblastomatosis and Wilms homozygous deletion displayed sub- spectrum of variants in as many tumor at an early age.8,9 stantially reduced ribonuclease activ- A B Fig. 2. Next-generation sequencing and PCR results showing homozygous deletion of DIS3L2 exon 9. A. Upper panel: screenshot from Integrative Genomics Viewer showing DIS3L2 exons 8, 9, and 10 of the patient’s sequencing data compared with a normal control. Sequence reads (red and blue boxes) are seen as expected in exons 8 and 10 of DIS3L2 in the patient, but no reads for exon 9 are present. Lower panel: zoom-in screenshot of exons 8, 9, and 10 of DIS3L2 in the patient compared with a normal control. B. PCR confirmation visualized by TapeStation: A1, ladder; B1, patient’s sample DIS3L2 exon 9 (no band); C1, control sample exon 9; D1, patient’s DIS3L2 exon 6 (patient intragenic control); E1, control sample exon 6; F1, blank. CAP TODAY | 3 ity compared with wild-type DIS3L2. hereditary cancer panel in a patient Stolte-Dijkstra I, van Essen AJ. Perlman syn- Additionally, loss of this gene in cell who died soon after birth. This result drome: four additional cases and review. Am lines led to increased rates of aneu- not only provides a molecular diagno- J Med Genet. 1999;86(5):439–446. ploidy, errors in mitosis, and abnormal sis of Perlman syndrome but also 5. Liban E, Kozenitzky IL. Metanephric ham- expression of mitotic proteins. carries important implications for the artomas and nephroblastomatosis in siblings. Cancer. 1970;25(4):885–888. In this case, a confirmed molecular family in its decision-making for fu- 6. Perlman M, Goldberg GM, Bar-Ziv J, Da- diagnosis of Perlman syndrome has ture pregnancies. Our experience novitch G. Renal hamartomas and nephro- two primary impacts on patient care. demonstrates that an NGS-based as- blastomatosis with fetal gigantism: a familial First, in a situation of a neonatal death, say can detect copy number variants syndrome. J Pediatr. 1973;83(3):414–418. a definitive diagnosis can help bring at the single exon level through use of 7. Perlman M, Levin M, Wittels B. Syndrome closure to the pregnancy for this fam- a carefully designed bioinformatics of fetal gigantism, renal hamartomas, and ily by providing a direct answer to pipeline and thorough sequence data nephroblastomatosis with Wilms’ tumor. Can- cer. 1975;35(4):1212–1217. what caused their loss. Second, and investigation. 8. Alessandri JL, Cuillier F, Ramful D, most significantly, this diagnosis has 1. Richards S, Aziz N, Bale S, et al. Standards et al. Perlman syndrome: report, prenatal important clinical implications for this and guidelines for the interpretation of se- findings and review. Am J Med Genet A. couple’s family planning and future quence variants: a joint consensus recom- 2008;146A(19):2532–2537. pregnancies. As part of the report is- mendation of the American College of Medi- 9. Perlman EJ. Pediatric renal tumors: practi- sued in this case, we recommended cal Genetics and Genomics and the Asso- cal updates for the pathologist. Pediatr Dev ciation for Molecular Pathology. Genet Med. Pathol. 2005;8(3):320–338. genetic testing for this family to aid in 2015;17(5):405–424. the assessment of recurrence risk. If 2. Astuti D, Morris MR, Cooper WN, et al. both parents are found to be asymp- Germline mutations in DIS3L2 cause the Dr. Wu and Dr. Schubert are clinical ge- tomatic carriers for heterozygous Perl man syndrome of overgrowth and nomic scientists, Dr. Zhao is genomic sec- pathogenic variants in DIS3L2, there Wilms tumor susceptibility. Nat Genet. 2012; tion lead scientist, Fanning is NGS analyst, is a 25 percent chance of their having 44(3):277–284. Fan is clinical laboratory section supervisor, another child with Perlman syndrome 3. Higashimoto K, Maeda T, Okada J, et al. and Dr. Li is vice chief—all in the Division of Genomic Diagnostics, Department of and a 50 percent chance of their hav- Homozygous deletion of DIS3L2 exon 9 due to non-allelic homologous recombina- Pathology and Laboratory Medicine, Chil- ing a child who is a carrier. tion between LINE-1s in a Japanese patient dren’s Hospital of Philadelphia. Dr. Sutton In sum, we identified a homozy- with Perlman syndrome. Eur J Hum Genet. is a pediatric pathologist, Department of Pa- gous deletion of a single exon of 2013;21(11):1316–1319. thology and Laboratory Medicine, Driscoll DIS3L2 gene using an NGS-based 4.
Recommended publications
  • Genetic Syndromes with an Increased Risk of Developing Cancer As an Example of the Use of New Technologies
    Genetics and Molecular Biology, 37, 1 (suppl), 241-249 (2014) Copyright © 2014, Sociedade Brasileira de Genética. Printed in Brazil www.sbg.org.br Review Article Impact of NGS in the medical sciences: Genetic syndromes with an increased risk of developing cancer as an example of the use of new technologies Pablo Lapunzina1,2, Rocío Ortiz López3,4, Lara Rodríguez-Laguna2, Purificación García-Miguel5, Augusto Rojas Martínez3,4 and Víctor Martínez-Glez1,2 1Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. 2Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 3Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León. Monterrey, Nuevo León, México. 4Centro de Investigación y Desarrollo en Ciencias de la Salud, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México. 5Unidad de Oncología Pediátrica, Hospital Infantil La Paz, Madrid, Spain. Abstract The increased speed and decreasing cost of sequencing, along with an understanding of the clinical relevance of emerging information for patient management, has led to an explosion of potential applications in healthcare. Cur- rently, SNP arrays and Next-Generation Sequencing (NGS) technologies are relatively new techniques used to scan genomes for gains and losses, losses of heterozygosity (LOH), SNPs, and indel variants as well as to perform com- plete sequencing of a panel of candidate genes, the entire exome (whole exome sequencing) or even the whole ge- nome. As a result, these new high-throughput technologies have facilitated progress in the understanding and diagnosis of genetic syndromes and cancers, two disorders traditionally considered to be separate diseases but that can share causal genetic alterations in a group of developmental disorders associated with congenital malformations and cancer risk.
    [Show full text]
  • Megalencephaly and Macrocephaly
    277 Megalencephaly and Macrocephaly KellenD.Winden,MD,PhD1 Christopher J. Yuskaitis, MD, PhD1 Annapurna Poduri, MD, MPH2 1 Department of Neurology, Boston Children’s Hospital, Boston, Address for correspondence Annapurna Poduri, Epilepsy Genetics Massachusetts Program, Division of Epilepsy and Clinical Electrophysiology, 2 Epilepsy Genetics Program, Division of Epilepsy and Clinical Department of Neurology, Fegan 9, Boston Children’s Hospital, 300 Electrophysiology, Department of Neurology, Boston Children’s Longwood Avenue, Boston, MA 02115 Hospital, Boston, Massachusetts (e-mail: [email protected]). Semin Neurol 2015;35:277–287. Abstract Megalencephaly is a developmental disorder characterized by brain overgrowth secondary to increased size and/or numbers of neurons and glia. These disorders can be divided into metabolic and developmental categories based on their molecular etiologies. Metabolic megalencephalies are mostly caused by genetic defects in cellular metabolism, whereas developmental megalencephalies have recently been shown to be caused by alterations in signaling pathways that regulate neuronal replication, growth, and migration. These disorders often lead to epilepsy, developmental disabilities, and Keywords behavioral problems; specific disorders have associations with overgrowth or abnor- ► megalencephaly malities in other tissues. The molecular underpinnings of many of these disorders are ► hemimegalencephaly now understood, providing insight into how dysregulation of critical pathways leads to ►
    [Show full text]
  • WES Gene Package Multiple Congenital Anomalie.Xlsx
    Whole Exome Sequencing Gene package Multiple congenital anomalie, version 5, 1‐2‐2018 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired‐end sequenced on the Illumina platform (outsourced). The aim is to obtain 8.1 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA‐MEM algorithm (reference: http://bio‐bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A4GALT [Blood group, P1Pk system, P(2) phenotype], 111400 607922 101 100 100 99 [Blood group, P1Pk system, p phenotype], 111400 NOR polyagglutination syndrome, 111400 AAAS Achalasia‐addisonianism‐alacrimia syndrome, 231550 605378 73 100 100 100 AAGAB Keratoderma, palmoplantar,
    [Show full text]
  • Mackenzie's Mission Gene & Condition List
    Mackenzie’s Mission Gene & Condition List What conditions are being screened for in Mackenzie’s Mission? Genetic carrier screening offered through this research study has been carefully developed. It is focused on providing people with information about their chance of having children with a severe genetic condition occurring in childhood. The screening is designed to provide genetic information that is relevant and useful, and to minimise uncertain and unclear information. How the conditions and genes are selected The Mackenzie’s Mission reproductive genetic carrier screen currently includes approximately 1300 genes which are associated with about 750 conditions. The reason there are fewer conditions than genes is that some genetic conditions can be caused by changes in more than one gene. The gene list is reviewed regularly. To select the conditions and genes to be screened, a committee comprised of experts in genetics and screening was established including: clinical geneticists, genetic scientists, a genetic pathologist, genetic counsellors, an ethicist and a parent of a child with a genetic condition. The following criteria were developed and are used to select the genes to be included: • Screening the gene is technically possible using currently available technology • The gene is known to cause a genetic condition • The condition affects people in childhood • The condition has a serious impact on a person’s quality of life and/or is life-limiting o For many of the conditions there is no treatment or the treatment is very burdensome for the child and their family. For some conditions very early diagnosis and treatment can make a difference for the child.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE Et Al
    US 20160281 166A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE et al. (43) Pub. Date: Sep. 29, 2016 (54) METHODS AND SYSTEMIS FOR SCREENING Publication Classification DISEASES IN SUBJECTS (51) Int. Cl. (71) Applicant: PARABASE GENOMICS, INC., CI2O I/68 (2006.01) Boston, MA (US) C40B 30/02 (2006.01) (72) Inventors: Arindam BHATTACHARJEE, G06F 9/22 (2006.01) Andover, MA (US); Tanya (52) U.S. Cl. SOKOLSKY, Cambridge, MA (US); CPC ............. CI2O 1/6883 (2013.01); G06F 19/22 Edwin NAYLOR, Mt. Pleasant, SC (2013.01); C40B 30/02 (2013.01); C12O (US); Richard B. PARAD, Newton, 2600/156 (2013.01); C12O 2600/158 MA (US); Evan MAUCELI, (2013.01) Roslindale, MA (US) (21) Appl. No.: 15/078,579 (57) ABSTRACT (22) Filed: Mar. 23, 2016 Related U.S. Application Data The present disclosure provides systems, devices, and meth (60) Provisional application No. 62/136,836, filed on Mar. ods for a fast-turnaround, minimally invasive, and/or cost 23, 2015, provisional application No. 62/137,745, effective assay for Screening diseases, such as genetic dis filed on Mar. 24, 2015. orders and/or pathogens, in Subjects. Patent Application Publication Sep. 29, 2016 Sheet 1 of 23 US 2016/0281166 A1 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS S{}}\\93? sau36 Patent Application Publication Sep. 29, 2016 Sheet 2 of 23 US 2016/0281166 A1 &**** ? ???zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz??º & %&&zzzzzzzzzzzzzzzzzzzzzzz &Sssssssssssssssssssssssssssssssssssssssssssssssssssssssss & s s sS ------------------------------ Patent Application Publication Sep. 29, 2016 Sheet 3 of 23 US 2016/0281166 A1 23 25 20 FG, 2. Patent Application Publication Sep. 29, 2016 Sheet 4 of 23 US 2016/0281166 A1 : S Patent Application Publication Sep.
    [Show full text]
  • 2012 2013 Causes of Birth Defects: Lessons from History 1 0 Drug
    cited Issue title 2012 2013 Vol.51 NO1 Causes of birth defects: Lessons from history 1 0 (2011) Drug safety in pregnancy: Utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information 3 0 Services Role of rare cases in deciphering the mechanisms of congenital 2 0 anomalies: CHARGE syndrome research Value of the small cohort study including a physical examination 2 0 for minor structural defects in identifying new human teratogens In vitro models of pancreatic differentiation using embryonic stem 2 1 or induced pluripotent stem cells Peptic ulcer disease with related drug treatment in pregnant 0 0 women and congenital abnormalities in their offspring Efficacy of medical care of epileptic pregnant women based on the 1 0 rate of congenital abnormalities in their offspring Rare clinical entity Perlman syndrome: Is cholestasis a new 0 0 finding? An unusual bronchopulmonary malformation in adulthood: Bronchial 0 0 atresia Vol.51 NO2 Effects of melanocortins on fetal development 0 0 (2011) Hypothyroidism caused by phenobarbital affects patterns of 0 0 estrous cyclicity in rats Adrenocorticotropic tumor cells transplanted into mouse embryos 0 0 affect pancreatic histogenesis Distribution of the longevity gene product, SIRT1, in developing 1 1 mouse organs Is there a reduction of congenital abnormalities in the offspring of diabetic pregnant women after folic acid supplementation? A 3 0 population-based case-control study Analysis of genitourinary anomalies in patients with VACTERL (Vertebral anomalies,
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
    US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008.
    [Show full text]
  • Tumor in Patients with 9Q22.3 Microdeletion Syndrome Suggests a Role for PTCH1 in Nephroblastomas
    European Journal of Human Genetics (2013) 21, 784–787 & 2013 Macmillan Publishers Limited All rights reserved 1018-4813/13 www.nature.com/ejhg SHORT REPORT Wilms’ tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas Bertrand Isidor*,1,2,14, Franck Bourdeaut3,4,5,14, Delfine Lafon6, Ghislaine Plessis7, Elodie Lacaze7, Caroline Kannengiesser8, Sylvie Rossignol9, Olivier Pichon1, Annaig Briand1, Dominique Martin-Coignard10, Maria Piccione11, Albert David1, Olivier Delattre2,Ce´cile Jeanpierre12, Nicolas Se´venet6 and Ce´dric Le Caignec1,13 Nephroblastoma (Wilms’ tumor; WT) is the most common renal tumor of childhood. To date, several genetic abnormalities predisposing to WT have been identified in rare overgrowth syndromes. Among them, abnormal methylation of the 11p15 region, GPC3 and DIS3L2 mutations, which are responsible for Beckwith–Wiedemann, Simpson–Golabi–Behmel and Perlman syndromes, respectively. However, the underlying cause of WT remains unknown in the majority of cases. We report three unrelated patients who presented with WT in addition to a constitutional 9q22.3 microdeletion and dysmorphic/overgrowth syndrome. The size of the deletions was variable (ie, from 1.7 to 8.9 Mb) but invariably encompassed the PTCH1 gene. Subsequently, we identified a somatic PTCH1 nonsense mutation in the renal tumor of one patient. In addition, by array comparative genomic hybridization method, we analyzed the DNA extracted from the blood samples of nine patients with overgrowth syndrome and WT, but did not identify any deleterious chromosomal imbalances in these patients. These findings strongly suggest that patients with constitutional 9q22.3 microdeletion have an increased risk of WT, and that PTCH1 have a role in the pathogenesis of nephroblastomas.
    [Show full text]
  • Beckwith-Wiedemann Syndrome
    560 Med Genet 1994;31:560-564 Syndrome of the month J Med Genet: first published as 10.1136/jmg.31.7.560 on 1 July 1994. Downloaded from Beckwith-Wiedemann syndrome Margaret Elliott, Eamonn R Maher In 1963 Beckwith' presented the necropsy find- features are most apparent before the age of 3 ings of three unrelated children with exompha- years, and after the age of 5 years there is often los, macroglossia, hyperplasia of the kidneys only minor dysmorphism. It is helpful to con- and pancreas, and adrenal cytomegaly, and sug- sider the complications of BWS by the age at gested that this might represent a new syn- presentation. drome. In 1964 Wiedemann2 published a case report of three sibs with exomphalos, macrog- lossia, and overgrowth. Subsequently more PRENATAL than 300 cases have been reported and the Exomphalos complicates approximately half incidence of Beckwith-Wiedemann syndrome the cases of BWS and will usually be picked up (BWS) has been estimated at 007 per 1000 on prenatal ultrasonography, but BWS is a births.34 rare cause of exomphalos (< 3% of all cases).6 Prenatal diagnosis of BWS has occasionally been reported after ultrasonographic detection Clinical features and natural history of a combination of abdominal wall defect, The clinical features of BWS are listed in the polyhydramnios, nephromegaly, and macro- table which is derived from the personal experi- glossia.7 BWS pregnancies are frequently com- ence of one of the authors (ME) of 69 cases in plicated by premature onset of labour. The risk the UK and 22 cases from the one other large of prematurity is associated with an increased clinical study published.5 Anterior abdominal incidence of polyhydramnios but not with fetal wall defects, macroglossia, pre- or postnatal overgrowth alone.
    [Show full text]
  • Cancer Prone Disease Section Mini Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Cancer Prone Disease Section Mini Review Perlman syndrome (renal hamartomas, nephroblastomatosis and fetal gigantism) Maria Piccione, Giovanni Corsello Dipartimento Materno-Infantile University of Palermo, Palermo, Italy Published in Atlas Database: December 2006 Online updated version: http://AtlasGeneticsOncology.org/Kprones/PerlmanID10117.html DOI: 10.4267/2042/38420 This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. © 2007 Atlas of Genetics and Cytogenetics in Oncology and Haematology Etiology: The genetic basis of the Perlman syndrome is Identity unknown and there is no conclusive laboratory test to Note: The Perlman syndrome is characterized by confirm the diagnosis. Although both sexes are polyhydramnios, fetal overgrowth, neonatal affected, the sex ratio is 2M:1F. The diagnosis is based macrosomia, high neonatal mortality, macrocephaly, on characteristic features and confirmed by histological dysmorphic facial features, visceromegaly, renal evidence. The syndrome has been described in nephroblastomatosis and a predisposition for Wilms both consanguineous and non-consanguineous tumor at very early age. couplings. Inheritance: Inheritance is of an autosomal recessive nature. Figure 1,2 : Macrocephaly, hypertelorism, epicanthus, broad flat nasal bridge, anteverted upper lip, axial hypotonia. Atlas Genet Cytogenet Oncol Haematol. 2007;11(2) 136 Perlman syndrome (renal hamartomas, nephroblastomatosis and fetal gigantism) Piccione M, Corsello G Figure 3 : Abdominal ultrasound scan at 6 months of age: nephromegaly with lobulated contoured kidneys and loss of corticomedullary differentiation. - Cardiomegaly. Clinics - Congenital heart disease: interrupted aortic arch and Phenotype and clinics anomalous coronary vessels and the dextroposition of the heart, muscular ventricular septal defect.
    [Show full text]
  • Syndromes and Constitutional Chromosomal Abnormalities
    Downloaded from jmg.bmj.com on May 16, 2013 - Published by group.bmj.com 705 REVIEW Syndromes and constitutional chromosomal abnormalities associated This article is available free on JMG online via the JMG Unlocked open access trial, with Wilms tumour funded by the Joint Information Systems Committee. For further information, see R H Scott, C A Stiller, L Walker, N Rahman http://jmg.bmjjournals.com/cgi/content/ full/42/2/97 ............................................................................................................................... J Med Genet 2006;43:705–715. doi: 10.1136/jmg.2006.041723 Wilms tumour has been reported in association with over Multiple nephrogenic rests throughout the kid- ney are sometimes present and can be referred to 50 different clinical conditions and several abnormal as nephroblastomatosis. constitutional karyotypes. Conclusive evidence of an The dramatic advances in the treatment of increased risk of Wilms tumour exists for only a minority of Wilms tumour are such that long term survival is now the norm: exceeding 90% for disease these conditions, including WT1 associated syndromes, localised to the abdomen (stages 1–3), and over familial Wilms tumour, and certain overgrowth conditions 70% in metastatic disease (stage 4).7 The treat- such as Beckwith-Wiedemann syndrome. In many reported ment of Wilms tumour is determined both by stage and histological classification of the conditions the rare co-occurrence of Wilms tumour is tumour, with treatment protocols varying probably due to chance. However, for several conditions between countries. Surgical resection is comple- the available evidence cannot either confirm or exclude an mented in the majority of individuals by chemo- therapy. Currently in the United Kingdom increased risk, usually because of the rarity of the around 30% of individuals with Wilms tumour syndrome.
    [Show full text]
  • Differential Diagnoses of Overgrowth Syndromes: the Most Important Clinical and Radiological Disease Manifestations
    Hindawi Publishing Corporation Radiology Research and Practice Volume 2014, Article ID 947451, 7 pages http://dx.doi.org/10.1155/2014/947451 Review Article Differential Diagnoses of Overgrowth Syndromes: The Most Important Clinical and Radiological Disease Manifestations Letícia da Silva Lacerda,1 Úrsula David Alves,1 José Fernando Cardona Zanier,1 Dequitier Carvalho Machado,1,2 Gustavo Bittencourt Camilo,1,2 and Agnaldo José Lopes2 1 Department of Radiology, State University of Rio de Janeiro, 20551-030 Rio de Janeiro, RJ, Brazil 2 Postgraduate Programme in Medical Sciences, State University of Rio de Janeiro, 20550-170 Rio de Janeiro, RJ, Brazil Correspondence should be addressed to Agnaldo Jose´ Lopes; [email protected] Received 12 March 2014; Revised 19 May 2014; Accepted 27 May 2014; Published 9 June 2014 Academic Editor: Andreas H. Mahnken Copyright © 2014 Let´ıcia da Silva Lacerda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Overgrowth syndromes comprise a heterogeneous group of diseases that are characterized by excessive tissue development. Some of these syndromes may be associated with dysfunction in the receptor tyrosine kinase (RTK)/PI3K/AKT pathway, which results in an increased expression of the insulin receptor. In the current review, four overgrowth syndromes were characterized (Proteus syndrome, Klippel-Trenaunay-Weber syndrome, Madelung’s disease, and neurofibromatosis type I) and illustrated using cases from our institution. Because these syndromes have overlapping clinical manifestations and have no established genetic tests for their diagnosis, radiological methods are important contributors to the diagnosis of many of these syndromes.
    [Show full text]